Suggested remit: To appraise the clinical and cost effectiveness of obinutuzumab within its marketing authorisation for treating lupus nephritis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6420

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6420 09 December 2024 - 20 January 2025

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
09 December 2024 In progress. Scoping commencing
29 November 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
29 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual